Solute carrier transporters (Kidney tubular) (SLC transporters)

Solute carrier (SLC) transporters in the kidney tubules represent a diverse superfamily of membrane-bound proteins essential for maintaining systemic homeostasis and renal function. These proteins are primarily localized in the proximal tubule, loop of Henle, and distal segments, where they facilitate the reabsorption of essential nutrients like glucose and amino acids, as well as the active secretion of metabolic waste and xenobiotics [1][2]. Prominent members include SGLT2 (SLC5A2), which is responsible for the majority of renal glucose reabsorption, and the SLC12 family, which regulates sodium, potassium, and chloride balance [2][4]. In various disease states, the dysregulation or genetic mutation of these transporters can lead to conditions such as type 2 diabetes, hypertension, and gout [3]. Therapeutically, these transporters are major targets; for instance, SGLT2 inhibitors are widely used to treat diabetes and heart failure by promoting glucosuria [4]. Additionally, renal SLCs like OAT1 (SLC22A6) and OAT3 (SLC22A8) are critical determinants of the pharmacokinetic profiles of many drugs, making them central to understanding and predicting drug-drug interactions [5]. This entry is marked as incorrect/broad because it refers to a heterogeneous group of proteins rather than a single specific molecular target.

Other names

SLC superfamilyRenal solute carriersKidney tubular transport proteinsRenal SLCs

Drugs targeting renal SLC proteins typically act as competitive or non-competitive inhibitors to block the reabsorption of solutes such as glucose or sodium, or to inhibit the secretion of organic ions, thereby modulating systemic metabolic levels or altering drug clearance rates [1][5].